Glofitamab, a CD20/CD3 bispecific antibody, in the treatment of R/R DLBCL

Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of glofitamab, a bispecific CD20-directed CD3 T-cell engager, in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Following promising results from a pivotal trial (NCT03075696), glofitamab received FDA approval for third-line use in adults. Dr Falchi notes ongoing research is now investigating glofitamab in earlier lines of therapy, which is the focus of the ongoing Phase III SKYGLO trial (NCT06047080). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.